KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Capital Expenditures (2017 - 2025)

Cardlytics (CDLX) has disclosed Capital Expenditures for 9 consecutive years, with $339000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 102.86% year-over-year to $339000.0, compared with a TTM value of $480000.0 through Dec 2025, down 69.27%, and an annual FY2025 reading of $480000.0, down 69.27% over the prior year.
  • Capital Expenditures was $339000.0 for Q4 2025 at Cardlytics, up from $7000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $12.5 million in Q3 2024 and bottomed at -$11.9 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $1.1 million, with a median of $355000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 2232.68% in 2022, while the deepest fall reached 930.63% in 2022.
  • Year by year, Capital Expenditures stood at $963000.0 in 2021, then crashed by 930.63% to -$8.0 million in 2022, then skyrocketed by 246.58% to $11.7 million in 2023, then plummeted by 201.16% to -$11.9 million in 2024, then skyrocketed by 102.86% to $339000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CDLX at $339000.0 in Q4 2025, $7000.0 in Q3 2025, and $15000.0 in Q2 2025.